mini-TIME: Preliminary Tissue Monitoring During Endovascular Intervention Study

Sponsor
Pedra Technology, PTE LTD (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT04956523
Collaborator
(none)
20
5

Study Details

Study Description

Brief Summary

Tissue perfusion assessment is key to more accurate measurement of foot ischemia, which is in turn an important factor in appropriate treatment decisions. In practice though, tissue perfusion measurements are not routinely undertaken as few practical solutions exist that are easy to use and fit in everyday clinical practice. Pedra has developed a novel easy to use, non-invasive device that can be used in practice to better inform treatment decisions.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Tissue perfusion assessment is key to more accurate measurement of foot ischemia, which is in turn an important factor in appropriate treatment decisions. In practice though, tissue perfusion measurements are not routinely undertaken as few practical solutions exist that are easy to use and fit in everyday clinical practice. Pedra has developed a novel, easy to use, non-invasive device that can be used in practice to better inform treatment decisions.

    This is a feasibility study to demonstrate the ability of the Xauron system to track tissue perfusion changes in patients undergoing endovascular intervention for the treatment of peripheral artery disease (PAD). The findings of this study are for research purposes and will also be used to help with the future education of physicians about the potential use of the Xauron system. In addition, this early pilot data will be used to help power larger, more definitive studies relating to the intra-procedural use of the Xauron system.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Preliminary Tissue Monitoring During Endovascular Intervention Study
    Anticipated Study Start Date :
    Oct 1, 2021
    Anticipated Primary Completion Date :
    Dec 1, 2021
    Anticipated Study Completion Date :
    Mar 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Integration of Xauron System into clinical workflow - The Investigator will complete a questionnaire assessing that the Xauron system can be integrated within the angiography suite for all subjects observed. [Measured at the SOC index procedure]

      To confirm that the Xauron system can be integrated into he angiography suite clinical workflow.

    Secondary Outcome Measures

    1. Relationship between interventional events of procedure and perfusion changed detected but the Xauron System [Measured at the standard of care (SOC) index procedure]

      Measure the time from end of an intervention to the zenith or nadir of the subsequent perfusion change

    2. Relationship of perfusion data from different anatomical locations during procedure [Measured at the SOC index procedure]

      Determine the ratio of perfusion in the arm relative to the foot after an intervention

    3. User feedback from the team in the angiographic suite [Measured at the SOC index procedure]

      To obtain user feedback from the team in the angiography suite to improve the user interface between the device and the operators.

    4. Angiographic images to evaluate and understand perfusion monitoring [Measured at the SOC index procedure]

      Collate data and angiographic images/video that may help endovascular teams understand and utilize perfusion monitoring in the angiography suite.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. The subject is undergoing endovascular intervention for the management of their PAD.

    2. The subject is between 40 to 90 years of age.

    3. Documented lower limb arterial occlusive or stenotic disease (using ankle-brachial index / pulse volume recording, duplex ultrasound or CT angiogram) within the last 8 weeks.

    4. In the opinion of the Investigator, the subject is willing and able to comply with the protocol and complete all protocol assessments.

    5. The subject has been informed of the nature of the study, agrees to its provisions and has willingly provided written informed consent, approved by the appropriate Institutional Review Board (IRB)

    Exclusion Criteria:
    1. Subjects on an investigational drug or being treated with an investigational therapeutic device, within 30 days of the study visit, that in the view of the Investigator might interfere with the study outcomes.

    2. Presence of a condition that the Investigator considers will compromise the subject's ability to participate in the study.

    3. Subjects on renal replacement therapy

    4. Signs of active infection causing localized inflammation on the plantar or dorsal surfaces of the foot.

    5. Lack of intact skin, or pathological skin conditions, at the proposed sensor pad positions that may impair or prevent the adherence of medical adhesives in general.

    6. Diabetic subjects with a Charcot neuropathic osteoarthropathy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Pedra Technology, PTE LTD

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Pedra Technology, PTE LTD
    ClinicalTrials.gov Identifier:
    NCT04956523
    Other Study ID Numbers:
    • CIP-003
    First Posted:
    Jul 9, 2021
    Last Update Posted:
    Jul 9, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 9, 2021